Preclinical Research Uses Oncolytic Adenovirus That Selectively Kills Cancer Cells While Revving Up The Immune System

Moffitt Cancer Center is working to develop a new cancer vaccine that could be used to treat several cancers by itself or in combination with other...

TIL Immunotherapy Offers Promising Results in Metastatic Non-Small Cell Lung Cancer

A group of investigators at Moffitt Cancer Center initiated a trial to determine if non-small cell lung cancer patients could have response to TIL...

Geriatric Oncology Offers Prolonged Life Spans for Older Cancer Patients

Many older cancer patients feel limited in their pursuit of cancer treatments. For geriatric oncology patients, the pros and cons of anti-cancer...

August is National Immunization Awareness Month

The summer is a time for many families to get caught up on immunizations. The summer of 2020 may be more important than previous summers as COVID-19...

Exploring Application of TILs for Head and Neck Cancers

Testing the feasibility of expanding tumor-reactive TIL from head and neck tumors for the development of a clinical trial

Researchers Use Intratumor Heterogeneity to Understand Eco-evolutionary Dynamics of Tumors

Researchers use the generalized diversity index (GDI) to quantify intratumor heterogeneity and further understand the eco-evolutionary dynamics of...

Optimizing Cancer Care Using Digital Technologies Requires Coordinated Multi-Stakeholder Effort

Data and technology have great potential to improve cancer care. But what are the priorities to maximize impact and how do we go about making them...

The World’s First T-cell Therapy for a Solid Tumor Cancer is Poised for Approval via Moffitt Partnership

Iovance’s investment is further proof that the Cellular Immunotherapy Program at Moffitt is a leading center for cell and gene therapy research

Stereotactic Body Radiation May be a Treatment Option for Unresectable Recurrent Head and Neck Cancers

Results of the study found that administering stereotactic body radiation therapy with concurrent Cisplatin is a well-tolerated and feasible...

The World’s First T-cell Therapy for a Solid Tumor Cancer is Poised for Approval via Moffitt Partnership (1)

Iovance’s investment is further proof that the Cellular Immunotherapy Program at Moffitt is a leading center for cell and gene therapy research

Veliparib Monotherapy Study Suggests Benefits for Advanced HER2 Negative Breast Cancer Patients

Veliparib may be a suitable treatment following the use of combination chemotherapy for a limited duration.

Novel Role of Specific Histone Deacetylase in Non-Small Cell Lung Cancer Discovered

Moffitt researchers conducted a series of preclinical studies to investigate the role of HDAC11 in NSCLC. They discovered that high levels of HDAC11...

Collaboration on New Developments for Robotic Lung Surgery Computer Interface

Dr. Jacques Fontaine and Dr. Eric Toloza are collaborating with researchers and engineers who are developing the computer interface enhancements for...